BL 7050

Drug Profile

BL 7050

Alternative Names: BL-7050

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ramot at Tel Aviv University
  • Developer BioLineRx
  • Class Analgesics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammatory pain; Neuropathic pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-pain in Israel (PO)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Neuropathic-pain in Israel (PO)
  • 07 Sep 2011 BL 7050 licensed to BioLineRx worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top